Agenus Inc. (AGEN) Insider Trading Activity

NASDAQ$6.73
Market Cap
$304.51M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
385 of 843
Rank in Industry
229 of 489

AGEN Insider Trading Activity

AGEN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Agenus Inc.

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Insider Activity of Agenus Inc.

Over the last 12 months, insiders at Agenus Inc. have bought $0 and sold $0 worth of Agenus Inc. stock.

On average, over the past 5 years, insiders at Agenus Inc. have bought $343,050 and sold $118,346 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 500,000 shares for transaction amount of $324,050 was made by ARMEN GARO H (See Remarks) on 2024‑02‑15.

List of Insider Buy and Sell Transactions, Agenus Inc.

2024-02-15PurchaseARMEN GARO HSee Remarks
500,000
0.0915%
$0.65
$324,050
-58.14%
2023-11-15PurchaseWIINBERG ULFdirector
25,000
0.0067%
$0.76
$19,000
-20.64%
2022-01-06SaleO'Day Steven JChief Medical Officer
38,679
0.0149%
$3.06
$118,346
-16.94%
2021-09-13SaleARMEN GARO HChairman and CEO
82,107
0.0357%
$6.50
$533,696
-56.93%
2021-09-10SaleKLASKIN CHRISTINE MPFO & PAO
11,120
0.0047%
$6.50
$72,280
-57.69%
2020-06-17SaleINCYTE CORP10 percent owner
283,840
0.1709%
$3.66
$1.04M
+4.04%
2020-06-16SaleINCYTE CORP10 percent owner
144,160
0.0877%
$3.66
$528,015
+4.63%
2020-06-15SaleINCYTE CORP10 percent owner
384,025
0.2247%
$3.57
$1.37M
+3.05%
2020-06-12SaleINCYTE CORP10 percent owner
9,100
0.0055%
$3.58
$32,556
+6.30%
2020-06-11SaleINCYTE CORP10 percent owner
183,875
0.1139%
$3.77
$692,786
+3.20%
2017-12-12SaleValentine KarenChief Legal Officer
16,716
0.0174%
$3.46
$57,842
-16.91%
2017-12-12SaleKLASKIN CHRISTINE MVP, Finance
11,220
0.0117%
$3.46
$38,836
-16.91%
2017-12-12SaleBaysal OzerChief Commercial Officer
7,424
0.0077%
$3.46
$25,691
-16.91%
2017-12-12SaleBuell JenniferChief Communications Officer
7,022
0.0073%
$3.46
$24,304
-16.91%
2017-12-12SaleDuncan AlexChief Technology Officer
13,092
0.0137%
$3.46
$45,302
-16.91%
2017-10-30PurchaseARMEN GARO HChairman & CEO
80,776
0.0835%
$3.61
$291,706
-2.11%
2017-10-27PurchaseARMEN GARO HChairman & CEO
119,224
0.1159%
$3.51
$418,524
-5.18%
2017-04-12PurchaseARMEN GARO HChairman & CEO
58,912
0.0604%
$3.29
$194,109
+18.52%
2017-04-10PurchaseARMEN GARO HChairman & CEO
141,088
0.1464%
$3.37
$474,930
+16.21%
2017-02-14PurchaseINCYTE CORP10 percent owner
20M
29.1662%
$6.00
$120M
-14.32%
Total: 123

Insider Historical Profitability

17.93%
INCYTE CORP10 percent owner
16972968
37.5122%
$114.23M15
<0.0001%
QVT Associates GP LLC10 percent owner
6915630
15.2843%
$46.54M01
ARMEN GARO HSee Remarks
625969
1.3835%
$4.21M266
+16.59%
WIINBERG ULFdirector
124063
0.2742%
$834,943.9920
<0.0001%
Valentine KarenChief Legal Officer
101521
0.2244%
$683,236.33015
KLASKIN CHRISTINE MPFO & PAO
93056
0.2057%
$626,266.88016
Sharp Shalinidirector
81311
0.1797%
$547,223.03215
+24.13%
HATSOPOULOS JOHNdirector
65000
0.1437%
$437,450.0030
+179.69%
O'Day Steven JChief Medical Officer
61321
0.1355%
$412,690.3301
Baysal OzerChief Commercial Officer
58790
0.1299%
$395,656.7011
+35.69%
Wentworth KerryVP, Clinical, Reg & Qual
57410
0.1269%
$386,369.30016
Buell JenniferChief Communications Officer
35656
0.0788%
$239,964.8801
Duncan AlexChief Technology Officer
21026
0.0465%
$141,504.9801
MARGARET EISENdirector
20000
0.0442%
$134,600.0020
+21.26%
Ballantyne Charles EvanChief Financial Officer
10000
0.0221%
$67,300.0010
<0.0001%
Wright Timothydirector
10000
0.0221%
$67,300.0010
<0.0001%
Thornton PeterCFO & Sr. VP
5000
0.0111%
$33,650.0010
+22.52%
SRIVASTAVA PRAMODdirector
1610
0.0036%
$10,835.3001
ATLEE FRANK V IIIdirector
0
0%
$001
AFEYAN NOUBARdirector
0
0%
$001
Malik Shahzaddirector
0
0%
$002

Historical Insider Profitability vs. Competitors

$24,384,691
42
-30.27%
$319.98M
$64,739,791
41
6.54%
$295.5M
Agenus Inc.
(AGEN)
$140,595,157
34
17.93%
$304.51M
$109,019,806
28
7.37%
$313.73M
$2,516,932
19
-15.78%
$280.88M
$10,399,379
13
13.60%
$320.09M
$57,263,116
11
-8.37%
$290.58M
$19,167,169
10
28.48%
$287.64M
$33,258,728
10
16.22%
$315.4M
$189,648
9
-52.20%
$266.66M
$6,847,110
9
5.96%
$334.92M
$13,043,783
8
732.82%
$276.12M
$73,966,461
8
6.13%
$301.98M
$301,686
5
-15.70%
$318.59M
$58,352
4
-43.78%
$263.5M
$32,007,657
4
-45.65%
$298.77M
$208,592
4
11.22%
$331.12M
$20,020,000
1
-75.24%
$312.31M
$63,731
1
-19.50%
$332.99M

AGEN Institutional Investors: Active Positions

Increased Positions46+42.2%3M+33.61%
Decreased Positions43-39.45%1M-16.37%
New Positions21New1MNew
Sold Out Positions12Sold Out211,439Sold Out
Total Postitions112+2.75%10M+17.24%

AGEN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$8,300.007.56%2.57M+36,983+1.46%2025-09-30
Siren, L.L.C.$3,438.003.13%1.06M00%2025-09-30
Morgan Stanley$1,774.001.62%549,126-228,879-29.42%2025-09-30
Blackrock, Inc.$1,767.001.61%547,112+43,024+8.54%2025-09-30
Bank Of America Corp /De/$1,193.001.09%369,314-51,364-12.21%2025-09-30
Millennium Management Llc$1,126.001.03%348,754-155,755-30.87%2025-09-30
Geode Capital Management, Llc$1,121.001.02%346,991+29,582+9.32%2025-09-30
Walleye Capital Llc$1,004.000.91%310,788+112,500+56.74%2025-09-30
Acadian Asset Management Llc$662.000.6%205,091+205,091New2025-09-30
Susquehanna International Group, Llp$617.000.56%190,954-11,179-5.53%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.